Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the interest coverage ratio high or low?
The interest coverage ratio of -203.41x is 76% below its 5-year average of -115.76x, around the middle of its 5-year range (-377.05x–-24.94x).
26.75% above its 12-month average of -277.68x.
Reported quarterly interest coverage; no daily interpolation. Q2 FY2026 (2026-06-30): -377.05x.
INTEREST COVERAGE RATIO
-203.41x
INTEREST COVERAGE RATIO AVG TTM
-277.68x
INTEREST COVERAGE RATIO AVG 3Y
-191.75x
INTEREST COVERAGE RATIO AVG 5Y
-115.76x
INTEREST COVERAGE RATIO AVG 10Y
N/A
INTEREST COVERAGE RATIO AVG 15Y
N/A
INTEREST COVERAGE RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
+26.75%
CURRENT VS 3Y AVG
-6.08%
CURRENT VS 5Y AVG
-75.71%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-6.03x
median of 502 covered companies
CURRENT VS SECTOR MEDIAN
-3276.10%
vs the sector median at left
SAB Biotherapeutics, Inc.
Market Cap
$270.62M
Interest Coverage Ratio
-203.41x
TTM Avg
-277.68x
3Y Avg
-191.75x
5Y Avg
-115.76x
Market Cap
$270.52M
Interest Coverage Ratio
-10.18x
TTM Avg
0.19x
3Y Avg
0.19x
5Y Avg
0.19x
Market Cap
$271.35M
Interest Coverage Ratio
-120.84x
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$271.10M
Interest Coverage Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$269.06M
Interest Coverage Ratio
-4.86x
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$267.65M
Interest Coverage Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$265.40M
Interest Coverage Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$264.16M
Interest Coverage Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$262.74M
Interest Coverage Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | INTEREST COVERAGE RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| SAB Biotherapeutics, Inc. (SABS) | $270.62M | -203.41x | -277.68x | -191.75x | -115.76x |
| Treace Medical Concepts, Inc. (TMCI)vs › | $270.52M | -10.18x | 0.19x | 0.19x | 0.19x |
| Rocket Pharmaceuticals, Inc. (RCKT)vs › | $271.35M | -120.84x | N/A | N/A | N/A |
| Fate Therapeutics, Inc. (FATE)vs › | $271.10M | N/A | N/A | N/A | N/A |
| TriSalus Life Sciences, Inc. (TLSI)vs › | $269.06M | -4.86x | N/A | N/A | N/A |
| Scribe Therapeutics Inc. (SCTX)vs › | $267.65M | N/A | N/A | N/A | N/A |
| OraSure Technologies, Inc. (OSUR)vs › | $265.40M | N/A | N/A | N/A | N/A |
| Eupraxia Pharmaceuticals Inc. (EPRX)vs › | $264.16M | N/A | N/A | N/A | N/A |
| EyePoint Pharmaceuticals, Inc. (EYPT)vs › | $262.74M | N/A | N/A | N/A | N/A |
| Inhibikase Therapeutics, Inc. (IKT)vs › | $263.41M | N/A | N/A | N/A | N/A |
Interest Coverage
-203.4x
Debt/Equity
0.02
Current Ratio
9.22
Formula: Interest Coverage = EBIT / Interest Expense
Reference ranges:
Note: Interest coverage should be compared with historical interest expense, operating income, and industry capital structure.
Interest Coverage = EBIT / Interest Expense
The interest coverage ratio measures operating earnings relative to interest expense.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | INTEREST COVERAGE RATIO |
|---|---|
| 2026-06-30 | -377.05x |
| 2026-03-31 | -318.72x |
| 2025-12-31 | -248.50x |
| 2025-09-30 | -292.87x |
| 2025-06-30 | -151.25x |
| 2025-03-31 | -154.85x |
| 2024-12-31 | -141.22x |
| 2024-09-30 | -144.92x |
| 2024-06-30 | -109.56x |
| 2024-03-31 | -149.15x |
| 2023-12-31 | -242.35x |
| 2023-09-30 | -76.37x |
| 2023-06-30 | -85.99x |
| 2023-03-31 | -80.12x |
| 2022-12-31 | -89.62x |
| 2022-09-30 | -110.54x |
| 2022-06-30 | -91.85x |
| 2022-03-31 | -93.13x |
| 2021-12-31 | -24.94x |
| 2021-09-30 | -50.80x |
| 2021-06-30 | -38.59x |
| 2021-03-31 | 10.82x |
